$ L$ C. a: ^% B+ u4 K9 Q临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:& Y; ] ]& d# o! W6 p( o2 I
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. j }0 O0 y7 Z, c+ y0 Rhttp://www.ncbi.nlm.nih.gov/pubmed/22968184/ X X# W) k/ W' O
" p X( b9 |- M. A/ f6 N6 W
依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制 - w U5 E$ o5 \http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx